Inhibrx, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Accretion of debt discount and non-cash interest expense
Stock-based compensation expense
Non-cash lease expense
Loss from equity method investment
Non-cash license revenue
Loss on disposal of fixed assets
Abandoned offering costs
Change in fair value of derivative liabilities
Change in fair value of warrant liabilities
Changes in operating assets and liabilities:
Accounts receivable
Receivables from related parties
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Accrued expenses and other current liabilities
Accrued expenses
Operating lease liability
Deferred revenue, current portion
Deferred revenue, non-current portion
Other non-current liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchase of fixed assets
Proceeds from the sale of fixed assets
Net cash used in investing activities
Cash flows from financing activities
Proceeds from initial public offering, gross
Costs associated with initial public offering
Proceeds from ATM offering
ATM Offering
IPO
Proceeds from issuance of common stock and pre-funded warrants in private placement
Issuance costs associated with issuance of common stock and pre-funded warrants in private placement
Proceeds from ATM offering
Costs associated with ATM offering
ATM Offering
IPO
Total costs associated with ATM offering
Proceeds from the issuance of debt
Payment of fees associated with debt
Proceeds from exercise of stock options
Proceeds from the issuance of preferred stock
Costs associated with the issuance of preferred stock
Proceeds from the issuance of convertible notes
Costs associated with the issuance of convertible notes
Repayment of principal on debt
Final payment on debt
Proceeds from the Paycheck Protection Program loan
Repayment of principal on the Paycheck Protection Program loan
Net cash provided by financing activities

Net increase in cash
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes
Supplemental schedule of non-cash investing and financing activities
Payable for purchase of fixed assets
Fair value of warrants issued to lender in conjunction with February 2022 Amendment (as defined in Note 3)
ATM offering costs included in accounts payable
ATM offering costs reimbursable in accounts receivable
Conversion of preferred stock to common stock
Conversion of the 2019 Note and the 2020 Notes to common stock
Debt discount arising from convertible note beneficial conversion features and reversal of beneficial conversion features
Operating lease liabilities arising from obtaining right-of-use assets
Derivative liabilities arising from the issuance of the 2019 Note and the 2020 Notes
Non-cash equity method investment
Reclassification of warrant liabilities to equity

Comments